Podcast: Play in new window | Download

Subscribe: TuneIn | RSS

This episode delves into the journey of Skyclarys, the first FDA-approved treatment for Friedreich’s ataxia (FA), a rare genetic disorder. The discussion features Dr. Colin Meyer, former executive at Reata Pharmaceuticals,  who shares his experiences from the inception of Reata to the acquisition by Biogen.

The conversation offers a compelling narrative of resilience, innovation, and collaboration in the pursuit of groundbreaking therapies for rare diseases. Colin’s reflections provide valuable perspectives on the challenges and rewards of drug development, as well as the transformative potential of scientific breakthroughs in improving patient outcomes.

Also in this episode:

• Sean visits Golden 1 Arena
• Newsworthy: Athlete With Cerebral Palsy Finishes The Barcelona Marathon
• Thank you notes: Kyle’s friends Blake & Dan and Sean’s friend Taylor 

Links and resources:

• rideATAXIA Hometown San Luis Obispo, CA. May 11, 2024
• Nic Novicki’s 2DD Episode
• Colin’s previous episode:
  • 035 – Drug Development – LIVE at REATA Pharmaceuticals
• Team FARA Himalayas Fundraising page
• Alex Roca finishing Barcelona Marathon
• Newsworthy music courtesy of Zapsplat.com